These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 8560288

  • 1. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 2. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Oct; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 3. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990 Oct; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 6. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Apr; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 7. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 8. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Feb; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G.
    Ann N Y Acad Sci; 2005 Feb; 1054():196-205. PubMed ID: 16339666
    [Abstract] [Full Text] [Related]

  • 10. Iron metabolism in thalassemia intermedia.
    Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.
    Haematologica; 1990 Feb; 75 Suppl 5():89-95. PubMed ID: 2086386
    [Abstract] [Full Text] [Related]

  • 11. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E, Baronciani D, Lucarelli G, Giardini C, Galimberti M, Polchi P, Martinelli F, Baldassarri M, Muretto P.
    Bone Marrow Transplant; 1993 Feb; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract] [Full Text] [Related]

  • 12. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Feb; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 13. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R.
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [Abstract] [Full Text] [Related]

  • 14. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Aug; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 16. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A.
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [Abstract] [Full Text] [Related]

  • 17. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.
    Kattamis CA, Kattamis AC.
    Semin Hematol; 1995 Oct; 32(4):269-79. PubMed ID: 8560284
    [No Abstract] [Full Text] [Related]

  • 18. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ.
    Haematologica; 1990 Oct; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract] [Full Text] [Related]

  • 19. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C, La Nasa G, Contu L, Galimberti M, Polchi P, Angelucci E, Baronciani D, Barbanti I, Muretto P, Lucarelli G.
    Bone Marrow Transplant; 1993 Oct; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract] [Full Text] [Related]

  • 20. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.